The FDA has approved the first permanent implant to relieve low or blocked urine flow in men aged 50 years and older with benign prostatic hyperplasia (BPH).
Manufactured by NeoTract, the UroLift System relieves urine flow by pulling back prostate tissue pressing on the urethra.
The FDA describes the device as a less invasive alternative to surgery for BPH treatment and an option for men who cannot tolerate available drug therapies.
Please login or register first to view this content.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Please login or register first to view this content.